The reduction in price target by Barclays, a major financial institution, could lead to a negative short-term impact on Bristol-Myers Squibb's stock price. This adjustment reflects a revised valuation by the analyst, potentially due to factors affecting the company's future earnings or market position. Investors often react to such changes in analyst ratings and price targets, which can result in stock price movements.